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Abstract  
 
The etiology of autoimmune hepatitis (AIH) is unknown, though hepatotropic viruses may 
be potential triggers. Hepatitis E virus (HEV) infection, an increasingly recognized cause 
of acute hepatitis, has been misdiagnosed as AIH due to the occurrence of autoantibodies 
during its acute phase. It has also been suggested that HEV infection may lead to or 
unmask AIH.  The prevalence of positive HEV serology has been ascertained in patients 
with AIH, but the prevalence of AIH-related autoantibodies in patients with HEV infection 
has not been systematically tested. We aimed to investigate whether acute HEV infection 
is associated with the presence of AIH-relevant autoantibodies, following the liver 
autoimmune serology guidelines of the International AIH Group. We tested 48 patients 
with acute HEV infection. Half of them had at least one autoantibody, 17% two 
autoantibodies. Anti-nuclear antibody (ANA) were detected in 16 (33%), anti-smooth 
muscle antibody (SMA) in 10 (21%), and anti-neutrophil cytoplasmic antibody (ANCA) in 
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7 (14.6%). Of note, two patients showed SMA with VG or VGT patterns and five had ANA 
with homogeneous appearance, both being typical of AIH type 1. Other AIH-specific 
autoantibodies were negative. Atypical anti-mitochondrial antibody, without evidence of 
primary biliary cholangitis, was positive in one patient, disappearing at follow-up. Follow-
up (median 12 months) serum was available from seven autoantibody positive patients: 
two became negative, while five remained positive, although no patient developed AIH to 
date. In conclusion, autoantibodies are frequently present during acute HEV infection, 
indicating that HEV should always be excluded before diagnosing AIH. Importantly, a 
minority of patients with acute hepatitis E develops AIH-specific autoantibodies, and, 
though they did not progress to autoimmune liver disease in the short-term, they warrant 
long-term monitoring.  
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Highlights 
• Non-specific liver autoantibodies are frequently positive in acute HEV infection 
• Specific liver autoantibodies are occasionally detected in acute HEV infection 
• Acute HEV should always be ruled out before diagnosing and treating autoimmune 
hepatitis 
• HEV patients with autoimmune hepatitis-specific positive serology should be followed 
up long term 
 
Introduction  
Hepatitis E (HEV) is an emerging cause of acute hepatitis in industrialized countries, 
where it is a food-borne zoonotic infection, transmitted mainly by uncooked or 
undercooked pork meat [1]. It is usually an acute self-limiting disease, but it can cause 
chronic infection with rapid progression to liver cirrhosis in organ transplant recipients, 
patients with hematological malignancies requiring chemotherapy, and individuals with 
HIV infection [1–3]. In Europe, the seroprevalence of HEV has been assessed in different 
countries, ranging from 0.6% and 52.5% [4]; in Switzerland a small study reported a 
seroprevalence of 4.9% [5], but a more recent and larger study analyzing 550 blood 
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donors reported  a seroprevalence ranging from 4.2% to 21.8% [6]. The high variability of 
these results is  due to the use of different techniques, since the sensitivity and specificity 
of the first-generation assays have been unsatisfactory [4, 6].   
Autoimmune hepatitis (AIH) is a rare, chronic inflammatory liver disease characterized by 
high transaminase and IgG levels, female preponderance, positive autoantibodies, 
histologically by interface hepatitis, and a swift response to steroid-based treatment [7]. 
Its etiology is still unknown. The disease is probably initiated by an autoantigen (as yet 
unidentified) presented to naive CD4+ T-helper (Th0) cells in the liver, in a genetically 
predisposed subject [7]. Viruses have been recognized as possible AIH triggers, mainly 
through a mechanism of molecular mimicry, a process that redirects immune responses 
to external pathogens to structurally similar self-components [8]. This concept is best 
documented in AIH type 2, where aminoacidic sequences of the hepatitis C (HCV) virus 
are shared in common with the auto-antigenic target, cytochrome P4502D6 (CYP2D6), of 
the anti-liver kidney microsomal 1 (LKM1) antibody, the disease hallmark [9]. Up to 10% 
of  HCV infected subjects are seropositive for anti-LKM1 [10, 11], and type 2 AIH following 
HCV infection has been reported [12].   
In one large German study  the  seroprevalence of HEV has been reported  to be higher 
in patients with AIH (7.7%) than  in blood donors (2%),  patients with rheumatoid arthritis 
(3.5%) or chronic hepatitis B and C infection (2.8%) [13]. The same group reported in a 
later study a higher HEV seroprevalence already at the time of AIH diagnosis [14].  
However, these results could not be reproduced in a cohort of AIH patients from the 
Netherlands [15], where the incidence of HEV is particularly high [16]. HEV IgG 
seroprevalence in both AIH and blood donors was around 27% [15]. Single cases of acute 
HEV infection with positive liver autoantibodies have been reported [17–21]. Taken 
together, these data raise the question whether HEV can trigger AIH.  
Autoantibodies are key to the diagnosis of AIH: presence of anti-LKM1 and/or anti-liver 
cytosol 1 (anti-LC1) antibodies define type 2 AIH, and > 95% of type 1 AIH patients are 
seropositive for anti-nuclear (ANA) and/or anti-smooth muscle antibodies (SMA) [22]. 
While the prevalence of positive HEV serology has been investigated in patients with AIH, 
no study to date has assessed the prevalence of AIH-related autoantibodies in patients 
with HEV infection. Thus, we aimed to investigate whether acute HEV infection is 
associated with the presence of AIH-relevant autoantibodies.  
 
Material and Methods  
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The project was approved by the Scientific Committee of the Swiss AIH cohort study. The 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and 
was approved by the local Ethics Committee. Written informed consent was obtained from 
each patient at study enrolment.  
Sera from 50 adult patients (> 16 years of age) with acute HEV infection diagnosed in the 
Ticino Canton between May 2015 and May 2017 were available for testing. Clinical 
information included: age, gender, pre-existing HCV, HBV or HIV infection, history of 
autoimmune diseases, concomitant type II diabetes mellitus, presence of cirrhosis, 
immunosuppression, current malignancies, alcohol and drug abuse, and extra-European 
travel in the last six months. Pre-existing AIH and chronic viremic HCV, HBV or HIV 
infections were exclusion criteria. Acute HEV infection was defined as positive HEV RNA in 
serum/plasma or feces, and/or combined positive serum anti-HEV IgG and IgM. HEV viral 
load was tested by Fast Track Diagnostic HEV; HEV serology was tested by ELISA Dia.Pro 
HEV IgG and Dia.Pro HEV IgM, respectively. All sera were collected before any treatment 
was began. The earliest available transaminase levels at presentation of HEV infection are 
reported, with an upper limit of normal of 35 IU/l. 
Autoimmune liver serology was analysed by indirect immunofluorescence (IIF) on rat kidney, 
liver and stomach tissue (Euroimmun) for detection of the following autoantibodies: anti-
SMA, anti-LKM1, anti-LC1, and anti-mitochondrial antibodies (AMA). IIF on HEp2 cells 
(Euroimmun) was used for ANA detection and pattern definition. All sera were analysed by 
immunoblot (Euroline Liver-Profile 2 IgG Euroimmun) for anti-soluble liver antigen (SLA), 
anti-LC1, anti-LKM1, anti-M2 (74 kDa E2 subunit of pyruvate dehydrogenase), anti-M2-3E 
(fusion protein from the immunogenic domains of E2 subunits of the three enzyme 
complexes representing the main autoantigens of the M2-antigen). Anti-neutrophil 
cytoplasmic antibody (ANCA) was tested by IIF on human granulocytes (Euroimmun) and 
any reactivity was further analysed by ANCA Profile ELISA IgG Euroimmun (proteinase 3, 
lactoferrin, myeloperoxidase, elastase, cathepsin G, bactericidal/permeability increasing 
protein). Sera from five well characterized AIH patients from the Swiss AIH cohort 
(NCT03146884) were used as autoantibody pattern controls. According to the consensus 
statement by the International AIH Group (IAIHG) [23], cut-off for autoantibody positivity in 
adults was established at 1:40, except for ANA, where the threshold for positivity on HEp2 
cells was established at 1:80. Patients with any positivity were invited to return for a follow-
up serum collection between 10 and 15 months after acute HEV infection.  
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Statistics 
Statistical analysis was performed with IBM-SPSS 23 for Windows. Chi-square or Fisher 
tests were used for assessing the association between presence of autoantibodies and age, 
gender, concomitant diabetes, cirrhosis, immunosuppression and extra-hepatic 
complications. The level of significance was set as α=0.05 two-tailed. 
Results 
Fifty adult patients with acute HEV infection were enrolled; two patients were excluded 
because of concomitant chronic HCV infection and pre-existing AIH, respectively. The 
remaining 48 patients met inclusion criteria; 67% were men, median age at HEV infection 
was 53.5 years (range, 17-83) (Table 1). All patients had positive IgM for HEV; HEV RNA 
was also positive in the serum or feces of 17 patients out of 40 tested. One female patient 
was diagnosed with coeliac disease at the same time as she presented with acute HEV 
infection (Table 1, patient 25). None of the patients had a history of recent extra-European 
travel. Five patients were taking immunosuppressive drugs at the time of HEV diagnosis, 
two because of kidney transplantation (patient 11: cyclosporin 50 mg/d and mycophenolate 
sodium 720 mg/d, reduced after HEV diagnosis; patient 23: azathioprine 75 mg/d and 
tacrolimus 4 mg/d) and one each because of sarcoidosis (patient 9: prednisone 20 mg/d), 
giant cell arteritis (patient 20: tocilizumab 8mg/kg body weight per month), and primary 
hypereosinophilic syndrome (patient 44: prednisone 5 mg/day and methotrexate 7.5 
mg/week); one further patient had chronic lymphocytic leukemia, but was on no treatment 
(Table 1). Nine patients had past or current autoimmune diseases (Table 1): two type I 
diabetes, and one each chronic inflammatory demyelinating polyneuropathy, systemic 
sarcoidosis, Hashimoto thyroiditis, giant cell arteritis, newly diagnosed coeliac disease, 
microscopic colitis, myasthenia gravis.  
Positive liver autoimmune serology was present in 54% of the patients, eight (17%) having 
two autoantibodies (Table 1).  
ANA was positive in one third of patients, with titers ranging from 1:80 to 1:640 (5 speckled, 
2 homogeneous, 2 nucleolar, 7 mixed pattern).  
SMA were detected in 10 patients (20.8%), with titers ranging from 1:40 to 1:320.  
ANCA were positive in 7 patients (14.6%), of whom three had cytoplasmic ANCA (cANCA), 
three peripheral anti-nuclear neutrophil antibodies (pANNA) and one had perinuclear ANCA 
(pANCA). Sera positive for ANCA at IIF on human granulocytes did not react with any of the 
main molecular ANCA targets as assessed by ELISAs.   
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AMA, the serological hallmark of primary biliary cholangitis (PBC), was not detected: 
however, one patient (Table 1, patient 31) showed an atypical AMA IIF pattern on triple 
rodent tissue (staining all renal tubules, gastric parietal cells and hepatocyte cytoplasm), but 
AMA was negative when tested against its immunochemically defined target antigens 
(Euroline Liver-Profile 2 IgG Euroimmun, as described above). The same patient was ANA-
positive, with a speckled IIF pattern on HEp2 cells.  
Anti-SLA, anti-LKM1 and anti-LC1 were negative in all patients.  
Transaminase levels at the time of HEV diagnosis were available for 47 patients, and were 
elevated in 36 (75%).  
SMA positivity was associated with ALT < 500 U/l (p=0.02) and there was a trend toward an 
association of SMA positivity with female gender (p=0.064), while ANA and ANCA positivity 
was not associated with ALT levels or gender. There was no statistically significant 
association of autoantibody positivity with age, presence of diabetes, cirrhosis, 
immunosuppression or extra-hepatic HEV complications. ANA positivity showed a trend 
toward association with the presence of concomitant autoimmune diseases (OR 4.4, CI 
95%: 0.9-21.6). 
At IIF on rat kidney tissue 2/10 SMA positive patients had the VG or VGT pattern, typical of 
AIH. The patient with the VG pattern (patient 29, Table 1) was a 77-year-old female with 
hypertension and hyperlipidemia, and a history of microscopic colitis treated by budesonide 
several years before HEV infection. She had mild, asymptomatic acute HEV infection, with 
rapid normalization of the transaminase levels, and absence of extrahepatic manifestations. 
The patient with the VGT pattern (patient 25) also had mild acute hepatitis; however, she 
was symptomatic because of neurological complications (neuralgic amyotrophy), and the 
diagnostic work-up for her elevated transaminase levels led to the diagnosis of celiac 
disease (positive anti-transglutaminase antibodies, duodenal biopsy showing Marsh 3B-3C 
[24]), which had been asymptomatic. In addition, one year after acute HEV infection she 
developed erythema nodosum and stage I pulmonary sarcoidosis. Her transaminase levels 
were normal three months after acute HEV infection. The patient with atypical AMA (patient 
31, Table 1), who was also positive for ANA with speckled IIF pattern, had no evidence of 
PBC (no symptoms, normal liver biochemical tests, normal upper abdomen ultrasound, 
normal liver stiffness measured by transient elastography). Overall there was no difference 
in prevalence and type of autoantibodies between the immunosuppressed and the 
remaining patients.  
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Follow-up serum from seven of the 26 patients who had positive autoimmune serology at 
the time of acute HEV infection, was available (Table 1) between 10 and 15 months later 
(median 12 months). Two patients were autoantibody negative at follow-up, three were still 
positive but at lower titers, and two had unchanged autoantibody specificities and titers. The 
patient with atypical AMA (patient 31) became negative for both AMA and ANA 10 months 
after acute HEV infection. The SMA-positive patient showing the VGT pattern (patient 25) 
was still SMA-positive one year later, but with the non AIH-specific V pattern, and had normal 
transaminase levels. She started a gluten-free diet three months after acute HEV infection. 
Follow-up serum from the SMA positive patient with the VG pattern (patient 29) was not 
available.  
None of the seven patients followed up for 15 months developed new serological positivities. 
Transaminase levels were normal at follow-up in all nine patients with available results 
(Table 1). All patients were followed-up in primary care, none was sent back to the 
hepatologist for persistent liver disease (median follow up: 20 months) except for patient 23, 
a kidney transplant recipient positive for both ANA and SMA, who developed chronic HEV 
infection (defined as persistent positive viremia after 6 months), and was treated with low-
dose ribavirin, leading to clearance of the infection one year later, when transaminase levels 
had normalized. 
 
Discussion 
We have tested systematically, following IAIHG guidelines [23], the whole panel of 
autoantibodies relevant to the diagnosis of autoimmune liver disease in a large cohort of 
patients with acute HEV infection. Just over 50% of our patients had positive autoantibodies, 
five having the ANA homogeneous pattern usually seen in AIH, and two the SMA pattern 
(VGT and VG) characteristic of AIH type 1. No patient had autoantibodies diagnostic for AIH 
type 2 (anti-LKM1 and anti-LC1) and no patient was positive for the AIH-specific anti-SLA. 
Autoantibody positivity, in particular in respect to SMA, is not unusual during the course of 
viral hepatitis, having been reported for hepatitis A, B, C and E [19, 25–29]. Usually, in the 
course of viral hepatitis SMA displays the non-specific V pattern [23], as detected in most of 
our HEV patients, and its presence is considered non-specific, though autoantibody 
positivity has been associated with more severe disease in chronic hepatitis C [30].  
Evolution from HAV, HCV and HEV infection to overt AIH has been anecdotally described 
[12, 21, 28, 31, 32], raising the question as to whether these viruses could be involved in 
the development of AIH and whether detection of autoantibodies typical of AIH during acute 
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viral infection may herald progression to autoimmune liver disease. Such an evolution has 
been documented for AIH type 2 in an instructive case report, where primary and secondary 
anti-LKM1 immune response after acute HCV infection prefigured the onset of overt AIH 
nine years later [12]. A multiple hit hypothesis was suggested in that case, as the patient 
had been exposed over the years to a number of viruses (herpes simplex, HCV, 
cytomegalovirus and Epstein Barr virus) that share amino acid sequences in common with 
the target of anti-LKM1 antibody, cytochrome P4502D6, resulting in the expansion of self 
cross-reactive lymphocyte populations through a mechanism of molecular mimicry until the 
occurrence of overt disease. 
That HEV can trigger or unmask AIH is suggested by two reports, one from Japan and one 
from Spain  [21, 28]. In the first report, a patient with acute HEV infection and positive ANA 
(IIF pattern not specified) was diagnosed with classical AIH five months after the acute 
episode, on the basis of chronic fatigue, negative HEV RNA in the blood, persistently 
elevated transaminase and IgG levels, positive ANA (1:640, pattern not reported) and typical 
histological findings [21]. A diagnosis of AIH following acute HEV infection is reported also 
in the Spanish series, in an ANA positive patient (pattern not described) with a prolonged 
hepatitis course despite clearance of HEV virus and liver histology compatible with AIH [28]. 
Though the patient did not fulfil the simplified IAIHG diagnostic criteria for AIH [33], there 
was an excellent response to steroids and azathioprine. Whether HEV played a direct role 
in the development of AIH or whether simply unveiled an underlying AIH in these two cases 
is unknown. 
Of importance in the clinical setting, presence of ANA and/or anti-SMA during acute HEV 
infection has led to the erroneous diagnosis of AIH and inappropriate immunosuppressive 
treatment in a number of published case reports [17–20, 34]. In none of these reports is 
there information on the immunofluorescence autoantibody appearance, which could have 
helped in discriminating between ANA and SMA patterns typically found in AIH and those 
present in a variety of other liver disorders, including viral hepatitis. 
In our series, seven patients were positive for ANCA, including pANCA, cANCA and atypical 
pANCA (pANNA). Interestingly, none of these autoantibodies reacted with any of known 
molecular targets of ANCA as assessed by ELISA in small-vessel vasculitis, AIH, 
inflammatory bowel disease and sclerosing cholangitis [22].  cANCA or pANCA were 
detected during acute HEV infection also in three of 23 patients in the above mentioned 
Spanish series [28], where positivity for ANA, ANCA or AMA was reported in 30%. It is 
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unclear whether other autoantibodies were sought and what techniques were used, but it is 
of interest that one of the Spanish patients, like one of our patients, was positive for AMA. 
AMA in our case was atypical, not showing the specificity characteristic of AMA in PBC when 
tested immunochemically, and was not associated with biochemical cholestasis; it 
disappeared at follow-up 10 months after acute HEV infection, with persistently normal liver 
biochemistry values, suggesting that it may be induced by HEV infection without impacting 
the course of the disease. Transient positivity for AMA has been reported in patients 
presenting with acute liver failure [35]. 
In our series, no patient went on developing AIH over a short follow-up period (median 
clinical follow up 20 months), including the two patients who, in association with ANA, had 
a SMA pattern considered AIH-specific. One of them, a SMA-positive lady with VGT IIF 
pattern, was diagnosed with celiac disease at the same time as acute HEV-infection, and 
developed erythema nodosum and pulmonary sarcoidosis one year later. The other patient, 
also female, had SMA with VG IIF pattern, and had a past history of microscopic colitis 
treated with budesonide. Both patients, therefore, appear to have a predisposition to the 
development of autoimmune diseases and merit longer term follow up to monitor possible 
progression to autoimmune liver disease.  
Extrahepatic autoimmunity is well documented in AIH patients, as 20% have concomitant 
autoimmune disorders, or will develop them during follow up, and up to 40% have a family 
history of autoimmune disease [7]. The association between AIH and celiac disease is also 
well described [36, 37]. It is conceivable that HEV infection might be one of multiple hits 
leading to AIH, as postulated in the above mentioned case of AIH following HCV infection 
[11, 38]. In this context it is of interest that in a series of 252 UK patients screened for 
autoantibodies, AIH-specific anti-SMA positivity presaged progression to AIH over a median 
follow up of 9 years in association with fluctuating transaminase levels, suggesting that our 
two patients should be followed up long-term [39].  
HEV is associated with extrahepatic manifestations, including, among others, Guillain-Barré 
syndrome, neuralgic amyotrophy,  thrombocytopenia, and glomerulonephritis, for which an 
immune-mediated mechanism has been  suggested [40–45].   The observation that HEV-
triggered immune-mediated phenomena are associated with less severe acute hepatitis [46] 
might explain the intriguing finding in our cohort that SMA positivity was associated with 
lower transaminase levels. As only one of our two patients with AIH-specific SMA had 
extrahepatic complications (neuralgic amyotrophy), it is not possible to speculate whether 
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these are linked to HEV infection, but further investigations are warranted. 
 
Conclusions 
In conclusion, our study underscores two important facts. On the one hand it shows that 
non-specific autoantibodies associated to AIH are frequently present during acute HEV 
infection. Clinicians should be aware of this and always exclude acute HEV infection before 
diagnosing and treating AIH, as immunosuppression can lead to chronic HEV disease [3]. 
On the other hand, it is conceivable that in predisposed subjects, HEV infection might trigger 
AIH: patients positive for AIH-specific serology, should be carefully followed up long-term.  
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  Table 1. Clinical features of the study population and results of liver autoimmune serology testing. 
 
 
Patient Gender Age ALT at HEV 
diagnosis 
(UI/l), ULN  
50 U/l 
ANA SMA ANCA Follow-up 
autoimmune 
serology 
Follow-up ALT 
levels (U/l), 
ULN 50 U/l 
Concomitant diseases 
1  M 44 50 - - -    
2 F 40 106 - - -    
3 M 50 29 1:80 spk - -    
4 M 83 21 - 1:80 V -   History of chronic inflammatory 
demyelinating polyneuropathy 
5 F 44 24 - - -    
6 M 52 639 - - -   Alcohol abuse, diabetes 
following pancreas surgery 
7 M 24 8 1:80 
spk/hom 
- -    
8 M 76 1445 1:160 spk     Type II diabetes 
9 M 57 26 - - -  34 Systemic sarcoidosis 
10 M 38 22 1:80 
spk/hom 
1:80 V -    
11 M 63 348 - - -   Kidney transplant recipient 
12 M 44 5457 - - -    
13 M 29 914 - - -    
14 F 42 88 - 1:160 V -    
15 M 48 558 - - -    
16 M 56 100 1:80 
spk/misp 
- -    
17 M 65 85 - - -    
18 F 70 1791 - - -   Type II diabetes 
  
19 F 45 25 1:320 spk - -   Hashimoto thyroiditis 
20 F 68 80 - - -    Giant cell arteritis, alcohol abuse 
21 M 46 210 - 1:80 V -   Type I diabetes, alcohol abuse 
22 M 78 3519 - - -   Type II diabetes 
23 F 54 521 1:160 spk 1:160 V - ANA neg, 
SMA 1:40v 
after 11 
months 
23 Kidney and pancreas transplant 
recipient, type I diabetes. 
Chronic HEV infection treated 
with RBV, virus cleared after 12 
months.  
24 F 40 n.a. - 1:80 V -    
25 F 51 251 1:640 
spk/misp 
1:320 
VGT 
- ANA 1:320 
spk, SMA 
1:160v after 
12 months 
16 (3 months 
after acute 
HEV infection) 
Celiac disease diagnosed at the 
same time as HEV. Erythema 
nodosum and sarcoidosis 1 year 
after HEV infection. 
26 F 53 390 - - -    
27 M 49 593 - - -    
28 M 74 1548 - - -   Type II diabetes 
29 F 77 92 1:80 hom 1:320 
VG 
-  22 (one month 
after acute 
HEV infection) 
Microscopic colitis many years 
before HEV infection 
30 M 62 53 - - -   Alcoholic liver cirrhosis, previous 
HCV cured 19 months before 
HEV infection. 
31* M 46 1552 1:160 
spk 
- - ANA and 
AMA neg 
after 10 
months 
5  
32 M 61 248 1:160 nuc - - ANA neg 
after 10 
months 
19  
  
 
None of the patients tested positive for antibodies to liver kidney microsomes, liver cytosol type 1 or soluble liver antigen 
33 F 70 3140 1:80 
spk/hom 
- -   Chronic lymphocytic leukaemia  
34 M 65 72 - 1:40 V -    
35 F 71 130 - - -    
36 M 62 1573 - - -  33 (two 
months after 
acute HEV 
infection) 
Type II diabetes 
37 M 46 3120 1:160 hom - -    
38 M 46 3057 1:80 
spk/nuc 
- -    
39 M 78 17 - - -    
40 F 17 250 - - -    
41 M 77 326 - - cANCA Unchanged 
cANCA after 
15 months 
29  
42 M 20 42 1:640 
spk/aca 
- pANCA ANA 1:320 
after 13 
months 
10  
43 F 56 52 - - pANNA    
44 M 74 32 - - cANCA   Primary hypereosinophilic 
syndrome 
45 M 76 2985 1:160 nuc - pANNA Unchanged 
after 12 
months 
 Myasthenia gravis 
46 F 52 65 - 1:80 V pANNA    
47 M 34 133 - - -    
48 M 63 1028 - - cANCA   Type II diabetes 
  
 
*Transiently positive for atypical anti-mitochondrial antibody (positive immunofluorescence, but negative immunoblot) 
 
ALT, alanine amino-transferase; ANA, anti-nuclear antibodies; SMA, smooth-muscle antibodies; pANCA, perinuclear anti-neutrophilic 
cytoplasmic antibody;  cANCA, cytoplasmic anti-neutrophilic cytoplasmic antibodies; pANNA, peripheral anti-nuclear neutrophilic antibodies; 
spk, speckled; misp, mitotic spindle; v, vessel; t, tubular; g, glomerular; hom, homogeneous; nuc, nucleolar; aca, anti-centromere;  ULN, upper 
limit of normal.  
 
 
 
 
